Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa

Johnson & Johnson declares quarterly dividend of $1.30 a share

New Brunswick, New Jersey-based Johnson & Johnson (NYSE:JNJ) said Friday that its board declared a cash dividend of $1.30 per share for the first quarter of 2026.

The dividend is payable March 10 to shareholders of record at the close of business on Feb. 24, with an ex-dividend date of Feb. 24.

Read more: Johnson & Johnson declares quarterly dividend of $1.30 a share
Grafa
Industrials

CNH taps Rivian and Nikola veterans for global leadership team

CNH Industrial N.V. (NYSE:CNH) announced on January 2, 2026, the strategic appointments of Carlo Materazzo as Chief Manufacturing Officer and Britton Worthen as Chief Legal and Compliance Officer, effective January 1, 2026.

The new appointments represent a significant infusion of talent from the high-growth electric vehicle and zero-emissions sectors.

Read more: CNH taps Rivian and Nikola veterans for global leadership team
Grafa
Technology

BitVentures launches digital assets segment with entry into cryptocurrency mining

BitVentures (NASDAQ:BVC), a technology-focused company recently rebranded from Santech Holdings and actively developing ventures in e-commerce, digital assets, and consumer healthcare, announced today the official launch of its new Digital Assets segment.

Read more: BitVentures launches digital assets segment with entry into cryptocurrency mining
Grafa
Health

Mesoblast reshuffles board for commercial pivot as Ryoncil sales surge

Mesoblast (NASDAQ:MESO) has implemented a sweeping reorganization of its Board of Directors, effective January 1, 2026, signaling a definitive shift from a research-heavy biotech to a revenue-driven commercial entity.

The leadership transition follows the company's most transformational period, highlighted by the December 2024 FDA approval and subsequent 2025 launch of Ryoncil (remestemcel-L).

Read more: Mesoblast reshuffles board for commercial pivot as Ryoncil sales surge